NRx Pharmaceuticals secured FDA fast-track status for NRX-100, a therapy drug, expanding its use to 13 million Americans. The drug may qualify for Accelerated Approval and a National Priority Voucher. Despite the news, shares fell 7.9% to $0.20 but sentiment turned "extremely bullish" amid high buzz.